Previous Article | Next Article ![]()
Infection and Immunity, April 1999, p. 1553-1559, Vol. 67, No. 4
Institute for Immunology, University of
Munich, 80336 Munich, Germany
Received 10 November 1998/Returned for modification 10 December
1998/Accepted 12 January 1999
Monocytes respond to lipopolysaccharide (LPS) stimulation with a
rapid expression of the tumor necrosis factor (TNF) gene. Upon repeated
LPS stimulation there is, however, little production of TNF mRNA and
protein; i.e., the cells are tolerant to LPS. Analysis of NF- Lipopolysaccharide (LPS) produced by
gram-negative bacteria will induce a pronounced activation of monocytes
and macrophages, a process mediated by the CD14 cell surface receptor
(35, 44). LPS-induced activation of monocytes leads to the
expression of a whole body of inflammatory mediators, including tumor
necrosis factor (TNF). TNF is a master cytokine that regulates a
plethora of inflammatory processes; in gram-negative sepsis, TNF forms a central element in the pathophysiology of the disease.
Exposure to LPS for a short period of time (1 h) may lead to enhanced
responses after secondary stimulation, a phenomenon frequently seen in
neutrophils and termed priming. LPS-primed neutrophils show enhanced
responses with respect to leukotrienes, reactive oxygen, and enzyme
release typically after stimulation with
formylmethionyl-leucyl-phenylalanine (29, 34). Priming may
also be observed for macrophages with respect to cytokine gene
expression (13). Here specific dose and time requirements have to be met. On the other hand, longer periods (days) of exposure to
LPS will lead after a second LPS stimulation to reduced cytokine production by monocytes/macrophages, a phenomenon termed LPS tolerance.
Decreased responses of tolerant monocytes have been documented not only
for TNF but also for interleukin-1 (IL-1), IL-6, and other cytokines,
for arachidonic acid metabolites, for responses like fever, and for
LPS-induced death rate (reviewed in reference 37).
In classical models of tolerance (for instance, to Characterization of the mobilized NF- This hypothesis was based on studies of DNA binding in gel shift assays
that do not allow for direct quantitation of the proteins involved. We
now show in Western blot analysis that upon LPS stimulation, the p65
protein is mobilized into the nucleus of tolerant cells as efficiently
as in naive cells. This demonstrates that the signal transduction
pathways leading to I (This work is part of S. Kastenbauer's thesis, completed at the
Ludwig-Maximilian-Universititaet Muenchen.)
Cell culture.
HEK 293 cells (kindly provided by D. Kuprash,
Moscow, Russia) were seeded at 5 × 105 cells per well
in six-well plates (product no. 3506; Costar, Bodenheim, Germany) in
RPMI 1640 (Biochrom, Berlin, Germany) supplemented with
L-glutamine (2 mm), penicillin (200 U/ml) plus streptomycin (200 µg/ml) (product no. 043-05140 H; Gibco), and 10% fetal calf serum. The cell line Mono Mac 6 was established from a patient with
monoblastic leukemia (43). The cell line shows many
characteristics of a human blood monocyte, including phagocytosis and
expression of the CD14 LPS receptor. These cells were cultured in
24-well plates in RPMI 1640 with L-glutamine, penicillin,
streptomycin, nonessential amino acids (product no. 043-01140 H; Gibco)
oxalacetic acid-sodium pyruvate-insulin supplement (product no. O-5003;
Sigma, Deisenhofen, Germany), and 10% fetal calf serum. The cells were controlled for absence of mycoplasma (38) on a weekly basis. Stimulation with LPS (Salmonella minnesota L-6261; Sigma)
was done in complete culture medium with a standard dose of 1 µg/ml. For tolerance induction, Mono Mac 6 cells were cultured for 2 to 3 days
with or without LPS at 20 ng/ml followed by stimulation for 1 to 6 h with LPS at 1 µg/ml.
TNF bioassay.
TNF bioactivity was measured in the WEHI
164/actinomycin D assay as described elsewhere (40). In
brief, WEHI 164 cells were exposed to actinomycin D for 2 h, and
the washed cells were added to threefold serial dilutions of
supernatants. After overnight culture, viability was determined by
using
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT, product no. 4251; Sigma), and concentrations (units per milliliter) were calculated with reference to a standard supernatant.
TNF reverse transcriptase PCR (RT-PCR).
TNF mRNA expression
was determined essentially as described elsewhere (6). In
brief, cell lysates were taken after 1 h of stimulation, and total
RNA was isolated and reverse transcribed with oligo(dT) primers. The
cDNA was then amplified with specific primers, and after 32 cycles the
product was separated on a 1.4% agarose gel in the presence of
ethidium bromide. As an external control, the housekeeping enzyme
Gel shift analysis.
Nuclear extracts from cells stimulated
as described above were prepared as described previously
(3). The protein concentration was determined by the method
of Bradford, using a commercial kit (product no. 500-0006; Bio-Rad,
Munich, Germany), and 6 to 10 µg of protein was incubated with
different double-stranded
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
NF-
B1 (p50) Is Upregulated in
Lipopolysaccharide Tolerance and Can Block Tumor Necrosis
Factor Gene Expression
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
B
proteins in gel shift assays demonstrated that the DNA binding activity
that is induced by LPS stimulation in tolerant cells consists mainly of
p50-p50 homodimers. Since p50 can bind to DNA but lacks a
transactivation domain, this may explain the blockade of TNF gene
expression. We now show that in the monocytic cell line Mono Mac 6, this inability to respond can be largely ascribed to NF-
B, since a
reporter construct directed by a trimeric NF-
B motif is strongly
transactivated by LPS stimulation of naive cells whereas LPS-tolerant
cells exhibit only low activity. Also, Western blot analyses of
proteins extracted from purified nuclei showed mobilization of
threefold-higher levels of p50 protein in tolerant compared to naive
cells, while mobilization of p65 was unaltered. Overexpression of p50
in HEK 293 cells resulted in a strong reduction of p65-driven TNF
promoter activity at the levels of both luciferase mRNA and protein.
These data support the concept that an upregulation of p50 is
instrumental in LPS tolerance in human monocytes.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-adrenergic
drugs), the respective cell surface receptor is downregulated or
uncoupled from downstream signalling (12). This does not appear to be the case in LPS tolerance since here the CD14 receptor is
unchanged or even enhanced in cell surface expression (17, 22,
45). Furthermore, signal transduction can still occur to some
extent since NF-
B was shown in some studies to be still mobilized
upon secondary stimulation (11).
B proteins revealed a
predominance of p50-p50 homodimers (8, 45). Since these p50 molecules lack a transactivation domain, we have hypothesized that upon
binding to the promoter of, for instance, the TNF gene, the p50
homodimers block transactivation by other NF-
B/Rel family members.
B degradation and subsequent nuclear location
of p65/Rel-A are still intact in LPS tolerance. On the other hand,
Western blotting for p50 protein after LPS stimulation showed
threefold-higher levels in tolerant compared to naive cells. With this
predominance of p50, the transactivation of an exclusively
NF-
B-directed reporter gene is strongly reduced, and we show for the
first time that overexpression of p50 can, in fact, block p65-driven
transactivation of the human TNF promoter. These data provide direct
evidence for the central role of p50 of NF-
B in preventing gene
expression in LPS tolerance.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-enolase was amplified (24).
B human TNF-605
oligonucleotides: coding strand 5'
AGCT TCCCCGGGGCTGTCCCAGG 3'
Western blotting. Cells were disrupted by Dounce homogenization in the presence of a proteinase inhibitor cocktail, and nuclei were purified over a sucrose gradient. Nuclear proteins were extracted, and 20 to 30 µg of protein/lane was separated on 4 to 12% Tris-glycine gels (product no. EC60385; Novex [obtained via Anamed, Offenbach, Germany]) and transferred to Hybond ECL (enhanced chemiluminescence) nitrocellulose membranes (product no. RPN 2020D; Amersham) by electroblotting. Membranes were reacted with 1:5,000 dilutions of antibodies against p50 (1141) and p65 (1226) that were kindly provided by Nancy Rice (Frederick, Md.). After reaction with F(ab)2 goat anti-rabbit immunoglobulin-peroxidase conjugate (1:10,000; product no. A6667; Sigma), blots were incubated with ECL reagent (product no. RPN 2106; Amersham) and exposed to Hyperfilm ECL (product no. RPN 3103; Amersham).
Plasmids and transfection.
The pTNF-1064 luci-
reporter
plasmid containing the human TNF 5' region was obtained by exchanging
the mouse
-globin promoter of the p
TATA.luci-
reporter plasmid
for the HindIII/BglII fragment from the TNF
5' region pxP2 luciferase construct (45). The p
TATA.luci reporter plasmid contains 3' to the luciferase gene the rabbit
-globin intron (15). The 3×
B.luc construct contains
three copies of the prototypic NF-
B sequence from the mouse kappa
light-chain enhancer cloned upstream of the TATA box of the
p
TATA.luci reporter plasmid (15).
1, split 1:2, and reseeded to ensure log-phase growth. On day 0, they were adjusted to 107/ml in RPMI 1640 without serum.
One milliliter of cells was then admixed with DEAE-dextran (product no.
D-1162; Sigma) at 62.5 µg/ml (final concentration) and a total of 5 µg of reporter plasmid. After incubation for 90 min at 37°C,
dimethyl sulfoxide (product no. 1.02931; Merck, Darmstadt, Germany) was
added at 10% (final concentration) for 3 min at room temperature.
Cells were then washed three times and seeded at 5 × 105/ml in 2-ml volumes per well in 24-well plates. After
overnight culture, 105 cells were then stimulated with
different LPS doses for various length of times as given below. The
standard dose of LPS was 1 µg/ml, and the standard time for
stimulation was 4 h for luciferase mRNA analysis and 6 h for
luciferase protein analysis.
For cotransfection analysis, HEK 293 cells were seeded at 5 × 105 cells per well in six-well plates (product no. 3506;
Costar) and cultured overnight. Duplicates of two wells each were then transfected by the calcium phosphate method with luciferase reporter plasmid alone (0.5 µg), with luciferase reporter plasmid plus 0.25 µg of RcCMVp65 (25) (kindly provided by P. A. Baeuerle, Freiburg, Germany), or with luciferase reporter plasmid plus
0.25 µg of RcCMVp65 plus either 2.5 µg of RcCMVp50 expression
plasmid or 2.5 µg of RcCMV empty expression plasmid. Cells were
washed after 6 h, and reporter gene activity was measured after
24 h.
Analysis of luciferase DNA and mRNA. The PCR procedure was performed essentially as described elsewhere (33). In brief, pellets of 105 cells each were lysed in 200 µl of RNAzol (WAK-Chemie, Bad Homburg, Germany). After addition of chloroform-isoamyl alcohol (24:1, vol/vol) and centrifugation at 10,000 × g, the aqueous phase was harvested and plasmid DNA and mRNA were isolated. This material was used directly for with 22 to 30 cycles of PCR with 5' and 3' primers that anneal to the plasmid DNA. For RT-PCR, the isolated mRNA was reverse transcribed with oligo(dT) primers and murine leukemia virus RT. The cDNA was then amplified for 34 to 40 cycles with the 3' primer spanning the intron of the luciferase reporter gene (15). Products were separated on 1.4% agarose gels containing ethidium bromide. Laser densitometry was used to quantify Polaroid negative films, and the amount of luciferase mRNA was expressed as the percentage of plasmid DNA signal.
Analysis of luciferase protein. Luciferase activity in cell lysates was determined by using a model LB9501 luminometer (Berthold, Wildbad, Germany) and the luciferase assay system (E1500) from Promega (Madison, Wis.).
Statistics. For statistical analysis, Student's t test (paired, log transformation) was used.
| |
RESULTS |
|---|
|
|
|---|
TNF gene expression in LPS tolerance. Human monocytic Mono Mac 6 cells in the absence of LPS produced little or no TNF mRNA and protein (Fig. 1A, lane 1). Stimulation with LPS at 1 µg/ml rapidly induced TNF mRNA within 1 h, and TNF protein in the supernatant showed a strong increase at 6 h (lane 2). When precultured with LPS at a low dose (20 ng/ml) for 2 days, the cells produced little TNF mRNA and protein without additional stimulation (lane 3); after stimulation with LPS at 1 µg/ml, there was no substantial expression of the TNF gene (lane 4). These data confirm earlier observations that the Mono Mac 6 cells which are stimulated during preculture with a low dose of LPS become tolerant to a second stimulation with a high dose of LPS (11, 45).
|
Reporter gene mRNA analysis: LPS dose response. Previous studies have shown that LPS tolerance is regulated at the level of TNF transcription (45). In earlier studies we analyzed the human TNF promoter by using standard luciferase reporter constructs (45). In the present study, we used reporter gene constructs that contain a large 3' intron which is spliced out with maturation of the mRNA. By using a transintron primer, the RNA for luciferase after reverse transcription can therefore be specifically amplified by PCR (15). Determination of plasmid DNA with a 3' primer that anneals downstream of the intron can then be used as an internal control to correct for different levels of plasmid in different samples of an experiment. When Mono Mac 6 cells were transfected with such TNF promoter-directed luciferase reporter constructs, LPS stimulation rapidly induced luciferase mRNA over a wide range of LPS doses (Fig. 2). Doses as low as 1 ng/ml induced a significant response; in some experiments not shown, doses of 100 and even 10 pg of LPS/ml were sufficient to transactivate the construct.
|
TNF promoter activity in LPS tolerance.
For analysis of TNF
promoter activity, naive and tolerant Mono Mac 6 cells were transfected
with the pTNF-1064 luci-
promoter reporter construct by using
DEAE-dextran, precultured with or without LPS at 20 ng/ml for 2 days,
washed, and stimulated with LPS at 1 µg/ml for 4 h. LPS
stimulation of the naive cells gave the expected strong response for
luciferase mRNA (26-fold activation compared to the unstimulated
control [Fig. 3A, lane 2). Cells precultured with LPS gave, however, only a minimal (threefold) transactivation (lane 4). Determination of luciferase enzyme activity gave a similar pattern, with a high activity in LPS-stimulated naive
cells (19-fold induction compared to the control [lane 2]), while
tolerant cells showed only a minimal (twofold) response (lane 4). These
data indicate that transactivation of the human TNF promoter reflects
the pattern of response seen for expression of the endogenous TNF gene
in LPS-tolerant human Mono Mac 6 monocytes.
|
NF-
B activity in LPS tolerance.
One crucial transcription
factor controlling expression of the TNF gene is NF-
B (27, 30,
36, 42). Previous studies using a human immunodeficiency virus
long terminal repeat reporter construct had indicated that function was
reduced in LPS tolerance (45). We now have analyzed the
activity of a luciferase reporter construct that contains a trimeric
NF-
B binding motif (15). With this construct, we obtained
essentially the same pattern of results as seen with the TNF
promoter-directed reporter plasmid. Again naive Mono Mac 6 cells gave a
strong induction of luciferase mRNA and protein after LPS stimulation
(142- and 158-fold, respectively [Fig.
4, lane 2). Tolerant cells showed only a
minimal induction of mRNA after LPS stimulation (1.3-fold). Luciferase
enzyme activity was still high in unstimulated tolerant cells (lane 3),
and fold induction compared to the unstimulated precultured cells (lane 4) was reduced to 3.9-fold. These data indicate that the reduced response of the human TNF promoter seen in LPS-tolerant monocytic Mono
Mac 6 cells may be largely due to a reduced activity of the NF-
B
transcription factor complex.
|
Nuclear NF-
B proteins in LPS tolerance.
Next we analyzed
the DNA binding activity for NF-
B in nuclear extracts of naive and
tolerant Mono Mac 6 cells. Similar to what had been reported earlier
(45), naive unstimulated cells showed a constitutive
high-mobility band (Fig. 5, lane 1); with LPS stimulation, an additional low-mobility band was detected (lane 2).
As shown previously, the low-mobility upper band consisted of p50-p65
heterodimers whereas the high-mobility lower band consisted of p50-p50
homodimers. In LPS-stimulated cells (lane 2), the p50-p65 band was
clearly stronger (>2-fold) than the p50-p50 band. In LPS-tolerant
cells, there was a higher intensity for the p50-p50 band even without
secondary stimulation (lane 3). With secondary stimulation there again
was mobilization of p50-p65, but p50-p50 predominated, the level being
twofold higher than that of p50-p65 (lane 4). These data on DNA binding
activity suggest that there is more p50 protein in the nuclei of
LPS-tolerant cells. To address this point directly, we analyzed by
Western blotting the abundance of p65 and p50 in highly purified
nuclei. Figure 6 (upper panel) demonstrates an LPS-induced mobilization of p65 in tolerant cells similar to what is seen in naive cells, which indicates that tolerant cells still respond to LPS stimulation by mobilization of NF-
B. Analysis of p50 revealed some constitutive p50 in naive cells and a
twofold increase after LPS stimulation (lower panel, lanes 1 and 2).
Cells precultured with LPS contain higher amounts of p50 in the nuclei,
and there was a further twofold increase after stimulation with LPS
(lower panel, lanes 3 and 4). In an average of three experiments, the
intensity of the p50 band in stimulated tolerant cells (lane 4) was
threefold higher than in stimulated naive cells (lane 2).
|
|
Overexpression of p50 blocks the human TNF promoter. The upregulated p50 protein in nuclear extracts of LPS-tolerant Mono Mac 6 cells suggests that p50 homodimers may bind to DNA and block expression of the TNF gene. We therefore examined whether overexpression of p50 can in fact block transactivation of the TNF promoter-driven luciferase reporter gene. For this, HEK 293 cells were transfected by calcium phosphate coprecipitation with the TNF promoter reporter plasmid plus a cytomegalovirus promoter-driven p65 expression plasmid. Figure 7 demonstrates that p65 can efficiently induce transcription from this construct, leading to high levels of luciferase mRNA and protein (lane 2). Cotransfection of p65 with an empty cytomegalovirus expression plasmid led to some nonspecific enhancement of expression (lane 4); when p65 was cotransfected with a p50 expression plasmid, however, there was a strong suppression of transactivation (lane 3) which on average was 6-fold for mRNA and 11-fold for enzyme activity. These data demonstrate that high levels of p50 can block transactivation of the human TNF promoter.
|
| |
DISCUSSION |
|---|
|
|
|---|
When monocytes are stimulated with LPS repeatedly, the initially strong response is minimal such that only low amounts of the proinflammatory cytokine TNF are produced. This LPS tolerance can be considered a protective mechanism that prevents damage to the body by avoiding excessive inflammation, for instance, in sepsis patients (5, 23, 32).
LPS tolerance may be regulated at the translational (20) and posttranslational (46) levels, but most studies have demonstrated a decrease in transcripts for TNF in tolerant cells (11, 21, 31). In the present study, we have confirmed that LPS tolerance in Mono Mac 6 cells accompanies a decreased level of TNF protein and mRNA. We now have analyzed in this system the regulation of the human TNF promoter by using a luciferase reporter gene construct that allows for determination of luciferase mRNA (15).
The approach of looking at mRNA rather then at the enzyme activity of a reporter protein is advantagous since it directly analyzes the transcription product independent of regulatory effects that may influence luciferase protein activity during or after translation. In fact, in some instances (e.g., Fig. 4) the analysis of mRNA gave a clearer pattern of results.
In Mono Mac 6 cells transfected with such constructs, transactivation
can occur at low levels of LPS. For the pTNF-1064 luci-
reporter
plasmid, for instance, 1 ng of LPS/ml will give a good response, but in
some experiments responses were noted at even the lower level of 10 pg/ml. Also, when the 3×
B.luc construct was used, LPS levels of 10 to 100 pg/ml induced significant reporter gene activity (data not shown).
These data on behavior of the TNF promoter in LPS tolerance are
consistent with earlier work (45). Much of the activity of
the TNF promoter is controlled by the transcription factor NF-
B
(27, 30, 42). For the human promoter, sites at
605 and
97 have been implicated (30, 36, 42). To further analyze a
possible contribution of NF-
B to LPS tolerance, we have analyzed the
activity of an artificial construct that contains a trimeric NF-
B
motif (15). In tolerant cells this construct showed strongly reduced LPS-induced transactivation (Fig. 4), further indicating that
LPS tolerance goes along with a reduced transactivating activity of the
NF-
B complex.
The human TNF promoter is controlled by additional transcription
factors such as C/EBP (25, 32), but we found no change in
DNA binding activity for C/EBP in LPS-tolerant Mono Mac 6 cells (unpublished data). In earlier work, we noted that LPS-tolerant Mono
Mac 6 cells upregulate p50 of NF-
B such that there is a predominance
of p50 homodimers (45). The same phenomenon has been
demonstrated for primary human monocytes (39) and in the mouse macrophage cell line P388 (41). In gel shift analyses, these p50 homodimers are detectable only when a DNA binding motif with
three cytosines at the 3' end, leading to a DNA sequence that is
partially palindromic, is used (8). In the present study, we
extend the finding of upregulated p50 by demonstrating with Western
blotting a threefold increase of p50 protein in nuclei of tolerant
cells compared to naive cells.
The p50 NF-
B protein lacks a transactivation domain, and p50-p50
homodimers when bound to DNA cannot transactivate but instead block
access of transactivating complexes like p50-p65. This will then result
in a blockade of gene expression. Consistent with this scenario
overexpression of p50 has been shown to downregulate the human
immunodeficiency virus long terminal repeat and the IL-2 promoter
(9, 14). As shown in the present report, overexpression of
p50 in HEK 293 cells results in a strong reduction of transactivation of the pTNF-1064 luci-
reporter plasmid (Fig. 7). These data demonstrate for the first time that overexpression of p50 can, in fact,
block activity of the human TNF promoter. The results support our
concept that the upregulated p50 may be instrumental in LPS tolerance.
This conclusion is consistent with findings of Goldring et al., who
analyzed the murine inducible nitric oxide synthase promoter by in vivo
footprinting (10). In these analyses, the NF-
B sites were
found occupied in LPS-tolerized murine macrophages. The LPS-tolerized cells also show a strong increase of a p50-p50 complex without secondary stimulation, suggesting that these homodimers occupy the
NF-
B sites of the inducible nitric oxide synthase gene. The data
suggest that upon secondary stimulation, the homodimers prevent access
of p65-containing heterodimers and thereby block transactivation.
With respect to stimulation by superantigen and by TNF, an upregulation
of p50 of NF-
B has been noted in other cellular systems of tolerance
(18, 28), suggesting that the mechanism of p50-mediated blockade of gene expression may have a more general importance. On the
other hand, LPS tolerance in other systems involving brief periods of
primary LPS exposure may be due to a blockade that is located further
upstream in the signalling cascade such that elements like I
B
kinases are not activated at all (16). Also, it has been
reported that in LPS-tolerant rat cells, all of the NF-
B
mobilization is blocked because of a depletion of p50 and p65 in the
cytosol (1). Still, data on LPS tolerance in rat macrophages
may not necessarily translate directly into the human system. In the
rat, G proteins are altered in LPS tolerance (2), while no
such alterations are detected in human cells (4).
Consistent with our concept, LaRue and McCall (19) noted
that in LPS-tolerant human monocytic cells I
B degradation still occurred, suggesting that NF-
B can still be mobilized. While there
are several mechanisms that may control TNF gene expression in LPS
tolerance, previous studies and the present report demonstrate a role
for upregulated p50 in blocking TNF transcription.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grants from Fritz Thyssen Stiftung, from Deutsche Forschungsgemeinschaft (SFB 217 and ZI 288/1-1), and from the VerUm Stiftung.
We acknowledge the expert technical assistance of G. Sulski and I. Petersmann and the generous provision of antibodies by Nancy Rice.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institute for Immunology, University of Munich, Goethestr. 31, 80336 Munich, Germany. Phone: 49 89 5996 676. Fax: 49 89 5996 680. E-mail: ziegler{at}ifi.med.uni-muenchen.de.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Blackwell, T. S.,
T. R. Blackwell, and J. W. Christman.
1997.
Induction of endotoxin tolerance depletes nuclear factor- B and suppresses its activation in rat alveolar macrophages.
J. Leukoc. Biol.
62:885-891[Abstract].
|
| 2. |
Coffee, K. A.,
P. V. Halushka,
S. H. Ashton,
G. E. Tempel,
W. C. Wise, and J. A. Cook.
1992.
Endotoxin tolerance is associated with altered GTP-binding protein function.
J. Appl. Physiol.
73:1008-1013 |
| 3. |
Dignam, J. D.,
R. M. Lebovitz, and R. G. Roeder.
1983.
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res.
11:1475-1489 |
| 4. | Durando, M., S. H. Ashton, M. A. Makhlouf, R. Simmons-Wagner, P. V. Halushka, and J. A. Cook. 1997. Endotoxin-induced desensitization of THP-1 cells is not associated with altered G protein binding or content. J. Endotoxin Res. 4:97-103. |
| 5. |
Ertel, W.,
J.-P. Kremer,
J. Kenney,
U. Steckholzer,
D. Jarrar,
O. Trentz, and F. W. Schildberg.
1995.
Downregulation of proinflammatory cytokine release in whole blood from septic patients.
Blood
85:1341-1347 |
| 6. | Frankenberger, M., H. Pechumer, and H. W. L. Ziegler-Heitbrock. 1995. Interleukin-10 is upregulated in LPS tolerance. J. Inflamm. 45:56-63[Medline]. |
| 7. |
Frankenberger, M.,
A. Pforte,
T. Sternsdorf,
B. Passlick,
P. A. Baeuerle, and H. W. L. Ziegler-Heitbrock.
1994.
Constitutive nuclear NF- B in cells of the monocyte lineage.
Biochem. J.
304:87-94.
|
| 8. |
Frankenberger, M., and H. W. L. Ziegler-Heitbrock.
1997.
LPS tolerance in monocyte/macrophages: three 3' cytospins are required in the DNA binding motif for detection of upregulated NF- B p50 homodimers.
Immunobiology
198:81-90[Medline].
|
| 9. |
Franzoso, G.,
V. Bours,
S. Park,
M. Tomita-Yamaguchi,
K. Kelly, and U. Siebenlist.
1992.
The candidate oncoprotein Bcl-3 is an antagonist of p50/NF- B-mediated inhibition.
Nature
359:339-342[Medline].
|
| 10. | Goldring, C. E., S. Reveneau, D. Pinard, and J. F. Jeannin. 1998. Hyporesponsiveness to lipopolysaccharide alters the composition of NF-kappaB binding to the regulatory regions of inducible nitric oxide synthase gene. Eur. J. Immunol. 28:2960-2970[Medline]. |
| 11. |
Haas, J. G.,
P. A. Bäuerle,
G. Riethmüller, and H. W. L. Ziegler-Heitbrock.
1990.
Molecular mechanisms in down-regulation of tumor necrosis factor expression.
Proc. Natl. Acad. Sci. USA
87:9563-9567 |
| 12. |
Hausdorff, W. P.,
M. G. Caron, and R. J. Lefkowitz.
1990.
Turning off the signal: desensitization of -adrenergic receptor function.
FASEB J.
4:2881-2889[Abstract].
|
| 13. | Hirohashi, N., and D. C. Morrison. 1996. Low-dose lipopolysaccharide (LPS) pretreatment of mouse macrophages modulates LPS-dependent interleukin-6 production in vitro. Infect. Immun. 64:1011-1015[Abstract]. |
| 14. |
Kang, S. M.,
A. C. Tran,
M. Grilli, and M. J. Lenardo.
1992.
NF- B subunit regulation in nontransformed CD4+ T lymphocytes.
Science
256:1452-1456 |
| 15. | Kastenbauer, S., A. Wedel, M. Frankenberger, T. Wirth, and H. W. L. Ziegler-Heitbrock. 1996. Analysis of promoter activity by polymerase chain reaction amplification of reporter gene mRNA. Anal. Biochem. 233:137-139[Medline]. |
| 16. |
Kohler, N. G., and A. Joly.
1997.
The involvement of an LPS inducible I B kinase in endotoxin tolerance.
Biochem. Biophy. Res. Commun.
232:602-607[Medline].
|
| 17. | Labeta, M. O., J.-J. Durieux, G. Spagnoli, N. Fernandez, J. Wijdenes, and R. Herrmann. 1993. CD14 and tolerance to lipopolysaccharide: biochemical and functional analysis. Immunology 80:415-423[Medline]. |
| 18. |
Lægreid, A.,
L. Thommesen,
T. Gullstein Jahr,
A. Sundan, and T. Espevik.
1995.
Tumor necrosis factor induces lipopolysaccharide tolerance in a human adenocarcinoma cell line mainly through the TNF p55 receptor.
J. Biol. Chem.
270:25418-25425 |
| 19. |
LaRue, K. E. A., and C. E. McCall.
1994.
A labile transcriptional repressor modulates endotoxin tolerance.
J. Exp. Med.
180:2269-2275 |
| 20. | Marchant, A., C. Gueydan, L. Houzet, Z. Amraoui, A. Sels, G. Huez, M. Goldman, and V. Kruys. 1996. Defective translation of tumor necrosis factor mRNA in lipopolysaccharide-tolerant macrophages. J. Inflamm. 46:114-123[Medline]. |
| 21. | Mathison, J. C., G. D. Virca, E. Wolfson, P. S. Tobias, K. Glaser, and R. J. Ulevitch. 1990. Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages. J. Clin. Investig. 85:1108-1118. |
| 22. | Mathison, J., E. Wolfson, S. Steinemann, P. Tobias, and R. Ulevitch. 1993. Lipopolysaccharide (LPS) recognition in macrophages. J. Clin. Investig. 92:2053-2059. |
| 23. | Munoz, C., J. Carlet, C. Fitting, B. Bisset, J.-P. Blériot, and J.-M. Cavaillon. 1991. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Investig. 88:1747-1754. |
| 24. | Pechumer, H., C. Bender-Götze, and H. W. L. Ziegler-Heitbrock. 1993. Detection of neuron specific gamma enolase (NSE) mRNA in normal human leukocytes by PCR with nested primers. Lab. Investig. 69:743-749[Medline]. |
| 25. | Pope, R. M., A. Leutz, and S. A. Ness. 1994. C/EBP beta regulation of the tumor necrosis factor alpha gene. J. Clin. Investig. 94:1449-1455. |
| 26. |
Schmitz, M. L., and P. A. Bäuerle.
1991.
The p65 subunit is responsible for the strong transcription activating potential of NF- B.
EMBO J.
10:3805-3817[Medline].
|
| 27. |
Shakov, A. N.,
M. A. Collart,
P. Vassalli,
S. A. Nedospasov, and C. V. Jongeneel.
1990.
B-type enhancers are involved in LPS-mediated transcriptional activation of the TNF- gene in primary macrophages.
J. Exp. Med.
171:35-47 |
| 28. |
Sundstedt, A.,
M. Sigvardsson,
T. Leanderson,
G. Hedlund,
T. Kalland, and M. Dohlsten.
1996.
In vivo anergized CD4+ T cells express perturbed AP-1 and NF- B transcription factors.
Proc. Natl. Acad. Sci. USA
93:979-984 |
| 29. |
Surette, M. E.,
N. Dallaire,
N. Jean,
S. Picard, and P. Borgeat.
1998.
Mechanisms of the priming effect of lipopolysaccharides on the biosynthesis of leukotriene B4 in chemotactic peptide-stimulated human neutrophils.
FASEB J.
12:1521-1531 |
| 30. |
Trede, N. S.,
A. V. Tsytsykova,
T. Chatila,
A. E. Goldfeld, and R. S. Geha.
1995.
Transcriptional activation of the human TNF- promoter by superantigen in human monocytic cells: role of NF- B.
J. Immunol.
155:902-908[Abstract].
|
| 31. |
Virca, G. D.,
S. Y. Kim,
K. B. Glaser, and R. J. Ulevitch.
1989.
Lipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells.
J. Biol. Chem.
264:21951-21956 |
| 32. | Wedel, A., G. Sulski, and H. W. L. Ziegler-Heitbrock. 1996. CCAAT/enhancer binding protein is involved in the expression of the tumor necrosis factor gene in human monocytes. Cytokine 8:335-341[Medline]. |
| 33. | Wilson, C. S., S. C. Seatter, J. L. Rodriguez, J. Bellingham, L. Clair, and M. A. West. 1997. In vivo endotoxin tolerance: impaired LPS-stimulated TNF release of monocytes from patients with sepsis, but not SIRS. J. Surg. Res. 69:101-106[Medline]. |
| 34. | Worthen, G. S., J. F. Seccombe, K. L. Clay, L. A. Guthrie, and R. Johnston. 1988. The priming of neutrophils by lipopolysaccharide for production of intracellular platelet-activating factor. Potential role in mediation of enhanced superoxide secretion. J. Immunol. 140:3553-3559[Abstract]. |
| 35. |
Wright, S. D.,
R. A. Ramos,
P. S. Robias,
R. J. Ulevitch, and J. C. Mathison.
1990.
CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.
Science
249:1431-1433 |
| 36. |
Yao, J.,
N. Mackman,
T. S. Edgington, and S.-T. Fan.
1997.
Lipopolysaccharide induction of the tumor necrosis factor- promoter in human monocytic cells.
J. Biol. Chem.
272:17795-17801 |
| 37. | Ziegler-Heitbrock, H. W. L. 1995. Molecular mechanism in tolerance to lipopolysaccharide. J. Inflamm. 45:13-26[Medline]. |
| 38. | Ziegler-Heitbrock, H. W. L., and R. Burger. 1987. Rapid removal of mycoplasma from cell lines mediated by a direct effect of complement. Exp. Cell Res. 173:388-394[Medline]. |
| 39. | Ziegler-Heitbrock, H. W. L., M. Frankenberger, and A. Wedel. 1995. Tolerance to lipopolysaccharide in human blood monocytes. Immunobiology 193:217-223[Medline]. |
| 40. | Ziegler-Heitbrock, H. W. L., E. Käfferlein, J. G. Haas, N. Meyer, M. Ströbel, C. Weber, and D. Flieger. 1992. Gangliosides suppress tumor necrosis factor production in human monocytes. J. Immunol. 148:1753-1758[Abstract]. |
| 41. |
Ziegler-Heitbrock, H. W. L.,
I. Petersmann, and M. Frankenberger.
1997.
p50 (NF- B1) is upregulated in LPS tolerant P388D1 murine macrophages.
Immunobiology
198:73-80[Medline].
|
| 42. |
Ziegler-Heitbrock, H. W. L.,
T. Sternsdorf,
J. Liese,
B. Belohradsky,
C. Weber,
A. Wedel,
R. Schreck,
P. Bäuerle, and M. Ströbel.
1993.
Pyrrolidine dithiocarbamate inhibits NF- B mobilization and TNF production in human monocytes.
J. Immunol.
151:6986-6993[Abstract].
|
| 43. | Ziegler-Heitbrock, H. W. L., E. Thiel, A. Fütterer, V. Herzog, A. Wirtz, and G. Riethmüller. 1988. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer 41:456-461[Medline]. |
| 44. | Ziegler-Heitbrock, H. W. L., and R. J. Ulevitch. 1993. CD14: cell surface receptor and differentiation marker. Immunol. Today 14:121-125[Medline]. |
| 45. |
Ziegler-Heitbrock, H. W. L.,
A. Wedel,
W. Schraut,
M. Ströbel,
P. Wendelgass,
T. Sternsdorf,
P. Bäuerle,
J. G. Haas, and G. Riethmüller.
1994.
Tolerance to lipopolysaccharide involves mobilization of nuclear factor B with predominance of p50 homodimers.
J. Biol. Chem.
269:17001-17004 |
| 46. | Zuckerman, S. H., G. F. Evans, Y. M. Snyder, and W. D. Roeder. 1989. Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression. J. Immunol. 143:1223-1227[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»